Gary Knopp

Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives

Retrieved on: 
Tuesday, October 10, 2023

Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.

Key Points: 
  • Knopp and Truwit will be taking on new roles as vice president of medical affairs and vice president of scientific affairs, respectively.
  • Dr. Knopp joined Hyperfine, Inc. in 2021 and brings three decades of experience in radiology, neuroradiology, and MR imaging.
  • In the role of vice president of scientific affairs, Dr. Chip Truwit will spearhead clinical innovation projects, supporting the Swoop® system’s continued advancement.
  • Dr. Chip Truwit joined Hyperfine, Inc. in 2022 and has over three decades of experience in academic and clinical radiology.

Blue Yonder Empowers Retailers with Supply Chain Powered Commerce at NRF 2023

Retrieved on: 
Monday, January 9, 2023

Blue Yonder will showcase its innovative capabilities and the retailers using them at its booth and in NRF programming.

Key Points: 
  • Blue Yonder will showcase its innovative capabilities and the retailers using them at its booth and in NRF programming.
  • Blue Yonder at the Microsoft Booth: In addition to its own booth, Blue Yonder will have a presence inside the Microsoft booth (#4503).
  • Stop by to learn how Blue Yonder’s Commerce solutions, integrated with Microsoft Azure, are helping retailers personalize the consumer journey with connected, customer-centric supply chains.
  • Engage with Blue Yonder at NRF:
    Join Blue Yonder at NRF 2023:

Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)

Retrieved on: 
Monday, February 28, 2022

Knopp Biosciences LLC today reported further clinical data from its Phase 2 Exhale trial demonstrating oral dexpramipexole improves airflow obstruction in asthma as measured by FEV1, largely through its effect on FVC.

Key Points: 
  • Knopp Biosciences LLC today reported further clinical data from its Phase 2 Exhale trial demonstrating oral dexpramipexole improves airflow obstruction in asthma as measured by FEV1, largely through its effect on FVC.
  • The data were presented over the weekend as a poster during the American Academy of Allergy Asthma & Immunology (AAAAI) meeting in Phoenix, AZ.
  • Treatments approved to date for eosinophilic asthma are monoclonal antibodies requiring injection or infusion; dexpramipexole is administered orally.
  • As previously reported, dexpramipexole was well tolerated in the EXHALE trial, with 97% of dexpramipexole-treated patients completing the primary assessment phase.